Bifidobacterium bifidum H22B664
Bifidobacterium bifidum H22B664 appears in a 2026 animal study examining postbiotics, bioactive compounds produced by fermentation, derived from Bifidobacteria-fermented tomato juice in relation to lipid metabolism in animal models exposed to microplastics. This is a single, early-stage preclinical study that has not been translated to human clinical outcomes. B. bifidum is a well-known species in infant and adult gut microbiome research, but strain-specific clinical evidence for H22B664 is not available in the indexed literature. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 1 body-system-tagged papers that concern each system. Research coverage, not measured effect.
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
1 papers reference this strain in the probiotic database.
Discussion
Be the first to comment.
Sign in to join the discussion.
Citations
Selected papers that name this strain.
-
[1]
Source →Postbiotic from Bifidobacteria-Fermented Tomato Juice Alleviates Lipid Metabolism Disorders Caused by Microplastics· Food Science and Human Wellness · 2026